Takeda Pharmaceutical Company Limited
TKPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.67 | -0.84 | 0.55 | -0.63 |
| FCF Yield | 9.12% | 3.56% | 5.09% | 16.73% |
| EV / EBITDA | 10.76 | 12.91 | 9.16 | 9.02 |
| Quality | ||||
| ROIC | 1.72% | 4.42% | 3.49% | 3.11% |
| Gross Margin | 65.51% | 66.43% | 69.11% | 68.99% |
| Cash Conversion Ratio | 9.78 | 4.97 | 3.08 | 4.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.39% | 6.11% | 7.99% | 2.74% |
| Free Cash Flow Growth | 187.57% | -31.40% | -63.35% | 21.00% |
| Safety | ||||
| Net Debt / EBITDA | 3.85 | 5.56 | 3.33 | 3.47 |
| Interest Coverage | 2.49 | 1.79 | 2.89 | 2.77 |
| Efficiency | ||||
| Inventory Turnover | 1.30 | 1.18 | 1.26 | 1.30 |
| Cash Conversion Cycle | 267.72 | 286.63 | 260.99 | 257.84 |